Monograph

N05AH02 - Clozapine

Propably not porphyrinogenic

Rationale

Substrate of CYP 1A2, 2C19, 2C8, 2C9, 2D6, 3A4 (major enzyme at higher concentrations), 2C19, 2E1. Inhibitor of CYP 3A4 (low potency), 2D6, 2C19, 2C9. References consider it safe for use. Observed not to be porphyrinogenic in long-term treatment of one patient (Sweden).

Chemical description

High-dose neuroleptic (benzodiazepine derivative) used in therapy resistent schizophrenia. Extensively metabolized via CYPs. South African list: use with care French list: use. See Holoryd S et al. Psychotropic drugs in acuteâ€¦(one case) (PMID: 10511069). Thunell; clinical experience from prolonged treatment (n=1): no porphyric side effects.

Personal communication

Report on uneventful use: One report of uneventful use of clozapine for 2-3 years in female AIP patient with known mutation. Porphyrin excretion low/normal during use. From Dr Salamanca, Madrid.

IPNet drug reports

Uneventful use reported in 1 patient with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes N05A / N05AH or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames